SCIENTIFIC AND ORGANIZING SECRETARIAT
PUBLI CREATIONS - Partner of AIM
27, Bd d’Italie - 98000 Monte-Carlo – Monaco
Ph +377 97973555
Fax +377 97973550
e-mail: ifmad@publiccreations.com
Website: www.aim-internationalgroup.com/2003/ifmad

CONGRESS VENUE
Monte-Carlo Grand Hotel
12, Av. des Spélugues
98000 Monte-Carlo – Monaco
Ph +377 93506500
Fax +377 93300157

On the cover: M.C. Escher “The Node”
It is our pleasure to welcome you in Monte-Carlo to the annual meeting of the International Forum on Mood and Anxiety Disorders (IFMAD).

IFMAD has become an important forum for the exchange of ideas on the latest developments in psychiatric treatments where international experts can address in an informal atmosphere some of the important topics in the field of mood and anxiety disorders. The meetings are particularly valued for the high quality of the scientific contributions and the opportunity for focused discussion of new data presented in a constructive and productive environment.

Attendees at previous meetings have appreciated the very efficient and agreeable formula provided by IFMAD meetings for keeping up to date with current treatment issues. We look forward to renewing old acquaintances at the next meeting and to welcoming an even wider audience.

We are pleased to have you with us again this year so that you have the opportunity to keep abreast of the latest advances.

Siegfried Kasper
Chairman

Stuart Montgomery
Co-Chairman
CHAIRMAN
Siegfried Kasper (Austria)

CO-CHAIRMAN
Stuart A. Montgomery (United Kingdom)

SCIENTIFIC ADVISERS
Christer Allgulander (Sweden)
A. Carlo Altamura (Italy)
David Baldwin (United Kingdom)
Graham Burrows (Australia)
Joseph Calabrese (USA)
Giovanni B. Cassano (Italy)
William F. Deakin (United Kingdom)
Koen Demyttenaere (Belgium)
Elias Eriksson (Sweden)
Teruhiko Higuchi (Japan)
Robert M.A. Hirschfeld (USA)
Sidney H. Kennedy (Canada)
Jean-Pierre Lépine (France)
Mario Maj (Italy)
Julien Mendlewicz (Belgium)
Hans-Jürgen Möller (Germany)
Franz Müller-Spahn (Switzerland)
Philippe H. Robert (France)
Alan F. Schatzberg (USA)
Dan J. Stein (South Africa)
Trisha Suppes (USA)
Eduard Vieta (Spain)
Lars von Knorring (Sweden)
Shigeto Yamawaki (Japan)
Joseph Zohar (Israel)
4  Forum Venue
5  Acknowledgements
6  Programme Overview
7  Scientific Programme
15  Posters
22  Scientific Information
23  General Information
26  Local Information
The Organising Committee express their gratitude to the following Companies

ASTRA ZENECA
BOEHRINGER INGELHEIM and ELI LILLY and COMPANY
H. LUNDBECK A/S
JANSSEN CILAG and ORGANON
for their contribution as Sponsors of Symposia

BOEHRINGER INGELHEIM and ELI LILLY and COMPANY
MARTIN DUNITZ
MERCK SHARP & DOHME
PIERRE FABRE MEDICAMENT
for their valuable co-operation

WISEPRESS Ltd
for their participation in the publication exhibition
<table>
<thead>
<tr>
<th>Time</th>
<th>Wednesday, November 19</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30/10.30</td>
<td>13.30/15.30 S01 “New bipolar antidepressants”</td>
</tr>
<tr>
<td>10.30/10.45</td>
<td>15.30/15.45 A European Depression Day</td>
</tr>
<tr>
<td>10.45/12.45</td>
<td>16.00/18.00 S02 “Monotheraphy, new experience with Risperidone in bipolar disease”</td>
</tr>
<tr>
<td>12.45/13.45</td>
<td>18.00/19.00 S03 Plenary Lecture “The search for genes of bipolar disorder: treatment implications”</td>
</tr>
<tr>
<td></td>
<td>Presentation IFMAD Award</td>
</tr>
<tr>
<td>13.00/18.00</td>
<td>19.00/20.00 Opening Reception</td>
</tr>
<tr>
<td>08.30/20.00</td>
<td>13.00/18.00 Poster Display</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Thursday, November 20</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30/10.30</td>
<td>08.30/10.30 S04 “Recent advances in treatment of anxiety disorder”</td>
</tr>
<tr>
<td>10.30/10.45</td>
<td>10.30/10.45 Coffee break</td>
</tr>
<tr>
<td>10.45/12.45</td>
<td>10.45/12.45 S05 “Depression and anxiety disorders – the importance of fast and effective treatment”</td>
</tr>
<tr>
<td>12.45/13.45</td>
<td>12.45/13.45 Lunch</td>
</tr>
<tr>
<td>13.45/15.45</td>
<td>13.45/15.45 S06 “New treatments for GAD”</td>
</tr>
<tr>
<td>15.30/15.45</td>
<td>15.30/15.45 S07 “Pain in psychiatric disorders”</td>
</tr>
<tr>
<td>16.00/18.00</td>
<td>16.00/18.00 S08 “The neurobiology of depression: bridging brain and body to achieve and retain remission”</td>
</tr>
<tr>
<td>18.00/20.00</td>
<td>18.00/20.00 S11 “New results in mania”</td>
</tr>
<tr>
<td>19.00/20.00</td>
<td>19.00/20.00 Poster Display</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Friday, November 21</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30/10.30</td>
<td>08.30/10.30 S09 “Controlling placebo”</td>
</tr>
<tr>
<td>10.30/10.45</td>
<td>10.30/10.45 Coffee break</td>
</tr>
<tr>
<td>10.45/12.45</td>
<td>10.45/12.45 S10 “Controlling mania with antipsychotic treatment”</td>
</tr>
<tr>
<td>12.45/13.45</td>
<td>12.45/13.45 Lunch</td>
</tr>
<tr>
<td>13.45/15.45</td>
<td>13.45/15.45 S11 “New results in mania”</td>
</tr>
<tr>
<td>15.45/16.00</td>
<td>15.45/16.00 S07 “Pain in psychiatric disorders”</td>
</tr>
<tr>
<td>16.00/18.00</td>
<td>16.00/18.00 S12 “New treatment for resistant or refractory depression”</td>
</tr>
<tr>
<td>18.00/20.00</td>
<td>18.00/20.00 S08 “The neurobiology of depression: bridging brain and body to achieve and retain remission”</td>
</tr>
<tr>
<td>19.00/20.00</td>
<td>19.00/20.00 Poster Display</td>
</tr>
<tr>
<td></td>
<td>08.30/18.00 Poster Display</td>
</tr>
</tbody>
</table>
Scientific Programme
WEDNESDAY, November 19, 2003

13.30 – 15.30 S01 NEW Bipolar Antidepressants

Chair: J. Angst (Switzerland), H. Aschauer (Austria)

S0101 Are atypical antipsychotics effective in bipolar depression?
H. Aschauer (Austria)

S0102 Long term treatment of bipolar depression
G. Evoniuk (USA)

S0103 The switch from depression to hypomania and mania: fact or fiction?
J. Angst (Switzerland)

S0104 Continuation treatment for mania: what happens to depression?
E. Vieta (Spain)

15.30 – 15.45 Presentation of a European Depression Day

M. Selo (Switzerland)
President of the Werner Alfred Selo Foundation

15.45 – 16.00 Coffee break
16.00 – 18.00  S02  MONOTHERAPHY, NEW EXPERIENCE WITH RISPERIDONE IN BIPOLAR DISEASE
Chair: S. Montgomery (United Kingdom)
S0201 The challenge of bipolar disorder for the patient if not properly diagnosed and treated
E. Vieta (Spain)
S0202 The use of atypical antipsychotics as monotherapy: new evidence for efficacy (short-term)
M. Eerdekens (Belgium)
S0203 The use of atypical antipsychotics as monotherapy: new evidence for efficacy (longer term)
S. Kasper (Austria)
S0204 Clinical trials vs clinical experience: special patient populations, defining the best dosage and best use of atypical antipsychotics in bipolar disorder
S. Montgomery (United Kingdom)

Sponsored by an unrestricted educational grant of JANSSEN-CILAG and ORGANON

18.00 – 19.00  S03  PLENARY LECTURE
Chair: S. Kasper (Austria)
The search for genes of bipolar disorder: treatment implications
J. Mendlewicz (Belgium)

Presentation of the International Forum Award established with the generous collaboration of MERCK SHARP & DOHME

19.00 – 20.00  Welcome cocktail
THURSDAY, November 20, 2003

08.30 – 10.30 S04 RECENT ADVANCES IN TREATMENT OF ANXIETY DISORDER
   Chair: M. Bourin (France), E. Eriksson (Sweden)
   S0401 Atypical antipsychotics in treating anxiety disorders
       J. Zohar (Israel)
   S0402 Is PMDD an anxiety disorder?
       E. Eriksson (Sweden)
   S0403 Recent advances in panic disorder
       M. Bourin (France)
   S0404 Recent advances in social phobia
       C. Allgulander (Sweden)

10.30 – 10.45 Coffee Break

10.45 – 12.45 S05 DEPRESSION AND ANXIETY DISORDERS – THE IMPORTANCE OF FAST AND EFFECTIVE TREATMENT
   Chair: D. Baldwin (UK), W. Burke (USA)
   S0501 Priorities in treating depression
       W. Burke (USA)
   S0502 How can the treatment of depression be optimised?
       S. Kasper (Austria)
   S0503 Escitalopram - a unique mechanism of action
       C. Sanchez (Denmark)
   S0504 Unmet needs in anxiety disorders - how can we improve treatment?
       D. Baldwin (United Kingdom)
   Sponsored by an unrestricted educational grant of
   H. LUNDBECK A/S

12.45 – 13.45 Lunch
THURSDAY, November 20, 2003

13.45 – 15.45 S06 NEW TREATMENTS FOR GAD
Chair: S. Montgomery (UK), R. Nil (Switzerland)

S0601 Pregabalin compared with other anxiolytics in GAD
R. Kavoussi (USA)

S0602 SSRIIs in the treatment of GAD
D. Baldwin (United Kingdom)

S0603 Discontinuation symptoms in SAD or GAD or depression
R. Nil (Switzerland)

S0604 Fast onset of response in GAD
S. Montgomery (United Kingdom)

15.45 – 16.00 Coffee Break

16.00 – 18.00 S07 PAIN IN PSYCHIATRIC DISORDERS
Chair: C. Allgulander (Sweden), A. Khan (USA)

S0701 Painful physical symptoms in depression
D. Perahia (United Kingdom)

S0702 Pregabalin and neuropathic pain
R. Kavoussi (USA)

S0703 Animal models and mechanisms
C. Sanchez (Denmark)

S0704 Venlafaxine and the control of pain
A. Partiot (USA)
18.00 – 20.00

S08 THE NEUROBIOLOGY OF DEPRESSION: BRIDGING BRAIN AND BODY TO ACHIEVE AND RETAIN REMISSION

Chair: S. Kasper (Austria)

S0801 Recognising and diagnosing depression: a paradigm shift
S. Montgomery (United Kingdom)

S0802 Is two better than one? Strategies to achieve remission
S. Kasper (Austria)

S0803 Dual-action antidepressants: the new frontier for the treatment of depression
A. Leuchter (USA)

*Sponsored by an unrestricted educational grant of BOEHRINGER INGELHEIM and ELI LILLY and COMPANY*
FRIDAY, November 21, 2003

08.30 – 10.30 S09  CONTROLLING PLACEBO
Chair : A. Khan (USA), S. Montgomery (UK)
S0901 Placebo trials in depression and anxiety
A. Khan (USA)
S0902 Rater training, certification and other myths
W. Potter (USA)
S0903 Severity increases assay sensitivity
A. Gerebtzoff (Switzerland)
S0904 Better monitoring, better patients
R. Buller (France)

10.30 – 10.45 Coffee Break

10.45 – 12.45 S10  CONTROLLING MANIA WITH ANTIPSYCHOTIC TREATMENT
Chair : G.B. Cassano (Italy)
S1001 Pharmacology of atypical antipsychotics in mania
L. Pani (Italy)
S1002 Mania treatment: use of atypical antipsychotics
A. Rotondo (Italy)
Sponsored by an unrestricted educational grant of
ASTRAZENECA ITALY

12.45 – 13.45 Lunch
FRIDAY, November 21, 2003

13.45 – 15.45 S11 NEW RESULTS IN MANIA
   Chair: J. Loftus (Monaco), E. Vieta (Spain)
   S1101 Risperidone in mania
      M. Eerdekens (Belgium)
   S1102 Quetiapine in mania
      M. Brecher (USA)
   S1103 Olanzapine in mania
      M. Tohen (USA)
   S1104 Ziprasidone in treatment of mania in bipolar disorder
      S. Romano (USA)

15.45 – 16.00 Coffee Break

16.00 – 18.00 S12 NEW TREATMENT FOR RESISTANT DEPRESSION
   Chair: J. Scott (UK), J. Tauscher (Austria)
   S1201 Augmentation therapy with psychotherapy in resistant depression
      J. Scott (United Kingdom)
   S1202 Are atypical antipsychotics antidepressants?
      G. Gharabawi (USA)
   S1203 SSRI and atypical antipsychotics in bipolar depression
      M. Tohen (USA)
   S1204 Current status of lithium augmentation in resistant depression
      J. Tauscher (Austria)

18.00 – 18.15 CLOSURE
P01. Borna disease virus in mood disorders and benefit of novel antiviral therapy
L. Bode¹, A. Auer², D.E. Dietrich³, H. Ludwig⁴ (¹Robert Koch Institut, Berlin, Germany, ²Psychiatrist in Practice, Linz, Austria, ³Medical School of Hanover, Hannover, Germany, ⁴Free University of Berlin, Berlin, Germany)

P02. Risk factors for post traumatic stress disorder after a road traffic accident
R. Coronas, J.M. Santos, X. Terrades, M. Ramos, G. Garcia Pares (Corporació Hospitalària Parc Taulí, Sabadell, Barcelona, Spain)

P03. Pharmacological difference between escitalopram and citalopram

P04. Depletion of serotonin in platelets after sertraline administration
M. Dannawi (Laboratory of Medical Analysis and Research, Tripolis – Lebanon)

P05. Successful treatment of refractory depression by combination of predisone with SSRIs.
M. Dannawi (Laboratory of Medical Analysis and Research, Tripolis – Lebanon)

P06. Comparison of sexual functioning in patients receiving duloxetine or paroxetine: acute- and long-term
Pl. Delgado¹, C.H. Mallinckrodt², F. Wang², P.V.Tran², S.K. Brannan², M.W. Wohlreich², D.G. Perahia³, M.J. Detke²,⁴,⁵ (¹Department of Psychiatry, Case Western Reserve University, Cleveland, OH, USA, ²Eli Lily and Company, Indianapolis IN, USA, ³Eli Lilly And Company, Erl Wood, UK, ⁴Department of Psychiatry, Indiana University Medical School, Indianapolis, IN, USA, ⁵Departments of Psychiatry, Mclean Hospital, Belmont, and Harvard Medical School, Boston, MA, USA)
P07. Duloxetine vs placebo in the prevention of relapse of major depressive disorder
M.J. Detke¹², I. Gilaberte¹, D.G. Perahia¹, F. Wang¹, T.C. Lee¹, P. Tran¹, C. Miner¹, S. Montgomery¹, (¹Eli Lilly and Company, Indianapolis, IN, USA, ²Department of Psychiatry, Indiana University Medical School, Indianapolis, IN, USA)

P08. Open-label pharmacokinetic study of quetiapine plus divalproex in patients with schizophrenic/schizoaffective disorders or bipolar disorder
C. L. DeVane¹, H. Winter², M. A. Smith² (¹Institute of Psychiatry, Medical University of South Carolina, Charleston, SC, USA, ²AstraZeneca, Wilmington, DE, USA)

P09. Potentiation of antidepressant treatment in resistant depression: a comparative study of seroquel versus lithium
J.P. Dorée, S.V. Tourjman, J. Desrosiers, R. Elie, S. Kuniki, C. Vanier (Centre de Recherche Fernand Seguin, Montréal, QC, Canada)

P10. Olanzapine/fluoxetine combination in rapid cycling bipolar disorder
S. Dubé¹², P.E. Keck², S.W. Andersen¹, A.R. Evans¹, M. Tohen¹³ (¹Lilly Research Laboratories, Indianapolis, IN, USA, ²Western Psychiatric Institute and Clinic, University of Pittsburgh, Pittsburgh, PA, USA, ³Department of Psychiatry, Harvard Medical School/Mclean Hospital, Belmont, MA, USA)

P11. Adjunctive ziprasidone in treatment-resistant depression: pilot study
D.L. Dunner¹, J.D. Amsterdam², R.C. Shelton³, H. Hassman⁴, M. Rosenthal⁵, S.J. Romano⁶ (¹University of Washington, Seattle, WA, USA, ²University of Pennsylvania, Philadelphia, PA, USA, ³Vanderbilt University, Nashville, TN, USA, ⁴Comprehensive Clinical Research CNS, Clementon, NJ, USA, ⁵BMR Health Quest, San Diego, CA, USA, ⁶Pfizer Inc, New York, NY, USA)
P12. Comprehensive pooled analysis of remission data: venlafaxine vs SSRIs (comparison)  
R. Entsuah¹, C. Nemeroff², I. Willard², M. Demitrack², M. Thase³, A. Lenox-Smith⁴ (¹Wyeth Research, Collegeville, PA, USA, ²Emory University School of Medicine, Atlanta, GA, USA, ³University of Pittsburgh Medical Center, Pittsburgh, PA, USA, ⁴Wyeth Pharmaceuticals, Taplow, UK)

P13. Meta-Analyses of duloxetine in the treatment of MDD  
B. Fallisard¹, M. Lothgren², D. Perahia³, A. Garcia-Cebrian⁴ (¹Département de Santé publique, Hôpital Paul Brousse, Paris, France, ²European Health Economics Ltd, Weybridge, UK, ³Eli Lilly & Co. Ltd, European Operations Medical, UK, ⁴Eli Lilly & Co. Ltd, European Health Outcomes Research, UK)

P14. Quetiapine monotherapy for mania associated with bipolar disorder  
M. Jones, K. Huizar (Pharmaceuticals, L.P, Wilmington, DE, USA)

P15. Factors of profession deficiency in panic disorder with agoraphobia  
M. Latas, V. Starcevic (Institute of Psychiatry KCS, Serbia and Montenegro)

P16. Cognitive impairment in late-onset depression  
J. Loftus, G. Colazzo (Service de Géronto-psychiatrie, Centre Hospitalier Princesse Grace, Monaco)

P17. Quetiapine combined with lithium or divalproex for the treatment of acute mania associated with bipolar disorder  
J. Mullen, B. Paulsson (AstraZeneca Pharmaceuticals, L.P., Wilmington, DE, USA)

P18. Does age of onset affect the course and severity of major depressive disorder?  
P19. Relationship between suicidality and co-morbid disorders

P20. Escitalopram and venlafaxine XR in the treatment of major depressive disorder (MDD) in a randomized, double-blind, fixed-dose study
R. J. Bielski¹, D. Ventura², C-C. Chang², L. Penatzer ² (¹Summit Research Network, ²Forest Laboratories, Inc., MI, USA)

P21. Psychiatric effects of three different interferon subtypes in chronic hepatitis patients: a comparison
G.I. Perini¹, C. Pavan¹, G. Ferri¹², S. Zanone Poma¹, E. De Toni², L. Chemello², E. Berardinello², F. Bergamaschi¹, A. Gatta², P. Amodio² (¹Dept. of Neuroscience-Section of Psychiatry-University of Padova, Italy, ²Dept. of Clinical and Experimental Medicine, University of Padova, Italy)

P22. Prazosin effects on specific symptoms in chronic combat trauma PTSD
M.A. Raskind¹², R.F. Barnes¹², E.R. Peskind¹², E.C. Petrie¹², C. Thompson¹², E. Kanter¹², A. Radant¹² (¹VA VISN 20 Mental Illness Research, Education and Clinical Center, Seattle, WA, USA, ²University of Washington School of Medicine, Seattle, WA, USA)

P23. The role of the R- and S-enantiomers in the efficacy of citalopram versus escitalopram
C. Sánchez, K.P. Bøgesø, B. Ebert, E.H. Reines, C. Bræstrup (H. Lundbeck A/S, Valby Copenhagen, Denmark)

P24. Clinical and neurobiological hypothesis in two cases of Cotard syndrome
M. Sarchiapone, G. Camardese, V. Carli, C. Cuomo, V. Faia, P. Madia, S. De Risio (Institute of Psychiatry, Catholic University of Sacred Heart, Roma, Italy)
P25. Bibliotherapy - cognitive-behavioral selfhelp in patients with partially remitted depression
M. Schlogelhofer¹, G. Wiesegger¹, U. Bailéi, H. Eder¹, U. Itzlinger¹, G. Jorgl¹, F. Leisch², M. Priesch¹, A. Schossèr¹, K. Hornik², U. Willinger¹, H.N. Aschauer¹ (¹University Hospital for Psychiatry, Department of General Psychiatry, Vienna, Austria, ²Department for Statistics and Probability Theory, Vienna University of Technology, Austria)

P26. Respiratory and autonomic panic disorder subtypes: clinical correlates and response to alprazolam-XR
E. Schweizer¹, B. Klee², C. Kremer² (¹University of Connecticut, Farmington, CT, USA, ²Pfizer Inc, New York, NY, USA)

P27. Ziprasidone in mania: 21-day randomized, placebo-controlled trial
S. Segal¹, R.A. Riesenberg², K. Ice³, P. English³ (¹Segal Institute for Clinical Research, North Miami, FL, USA, ²Atlanta Center for Medical Research, Decatur, GA, USA, ³Pfizer Global Research and Development, New London, CT, USA)

P28. The speed of onset of action of alprazolam-XR compared to alprazolam-CT in panic disorder
D. Sheehan, K. Harnett-Sheehan, A. Raj (University of South Florida, College of Medicine Dept. Psychiatry, Tampa, FL, USA)

P29. Panic cognitions and response to pharmacotherapy of panic disorder with agoraphobia
V. Starcevic¹, C. White², L. Birner², M. Latas², D. Kolar² (¹Nepean Hospital, University of Sydney, Penrith, NSW, Australia, ²University of Newcastle, Newcastle, NSW, Australia)

P30. Anxiety and the prevalence of major depressive disorders
J.G. Stefansson¹, H. Kolbeinsson¹, H. Oskarsson², E Líndal¹, Th. Thorgerisson³, J. Gulcher³, K. Stefansson³ (¹Landspitali-University Hospital Reykjavik, ²Therapeia and ³deCode Genetics, Reykjavik, Iceland)
P31. Milnacipran in adolescents suffering from major depression and/or dysthymia
S. Tauscher-Wisniewski¹, M.H. Friedrich¹, J. Tauscher ² (Depts. of ¹Neuropsychiatry for Children & Adolescents, and ²General Psychiatry, University of Vienna, Austria)

P32. Remission in placebo-controlled trials of duloxetine with an SSRI comparator
M.E. Thase¹, Y. Lu², M.J. Joliat², T. Treuer², M.J. Detke²,³,⁴ (¹Department of Psychiatry, University of Pittsburgh Medical Center, Pittsburgh, PA, USA, ²Eli Lilly and Company, Indianapolis, IN, USA, ³Department of Psychiatry, Indiana University Medical School, Indianapolis, IN, USA, ⁴Departments of Psychiatry, McLean Hospital, Belmont, MA and Harvard Medical School, Boston, MA, USA)

P33. Olanzapine versus placebo for relapse prevention in bipolar depression
M. Tohen¹,², C. Bowden², J. Calabrese³, JC-Y Chou⁴, T. Jacobs⁴, R.W. Baker¹, D. Williamson¹, A.R. Evans¹ (¹Research Laboratories, Indianapolis, IN, USA, ²Department of Psychiatry, Harvard Medical School/McLean Hospital, Belmont MA, USA, ³Dept. Of Psychiatry, Case Western Reserve Univ. Univ. Hospitals of Cleveland, OH, USA, ⁴NYU School of Medicine, New York, NY, USA)

P34. Olanzapine versus lithium in relapse prevention in bipolar disorder
M. Tohen¹,², A. Marneros² C. Bowden³, R.W. Baker¹, A.R. Evans¹, G. Cassano¹ (¹Lilly Research Laboratories, Indianapolis, IN, USA, ²Department of Psychiatry, Harvard Medical School/ McLean Hospital, Belmont, MA, USA, ³Department of Psychiatry, University of Texas Health Science Center, San Antonio, TX, USA, ⁴Department of Psychiatry, University of Pisa, Pisa, Italy)

P35. Quetiapine treatment of borderline personality disorder
E. Villeneuve, S. Lemelin (Clinique Le Faubourg St-Jean, Centre Hospitalier Robert-Giffard, Québec, Canada)
P36. Anxiolytic activity of propoten: involvement of GABA in this effect

T.A. Voronina, G.M. Molodavkin, J.L. Dugina, S.A. Sergeeva, O.I. Epstein (Institute of Pharmacology RAMS, NPF “Materia Medica Holding”, Moscow, Russia)

P37. Adjunctive ziprasidone for acute bipolar mania: randomized, placebo-controlled trial

R. Weisler¹, J. Dunn², P. English² (¹University of North Carolina at Chapel Hill, Department of Psychiatry, Raleigh, NC, USA; ²Pfizer Global Research and Development, New London, CT, USA)

P38. Onset of improvement in emotional and painful physical symptoms of depression with duloxetine treatment

M.M. Wohlreich¹, S.K. Brannan¹, C.H. Mallinckrodt¹, M.J. Detke¹,²,³, Y. Lu¹, J.G. Watkin¹, T. Treuer¹, G. Tollefson¹ (¹Eli Lilly and Company, Indianapolis, IN, USA; ²Department of Psychiatry, Indiana University Medical School, Indianapolis, IN, USA; ³Eli Lilly and Company, Vienna, Austria)

P39. Bright light therapy in seasonal affective disorder – does it suffice?

E. Pjrek, D. Winkler, A. Konstantinidis, N. Thierry, A. Heiden, S. Kasper (Department of General Psychiatry, University of Vienna, Vienna, Austria)

P40. Seasonality of birth in seasonal affective disorder

E. Pjrek, D. Winkler, J. Stastny, A. Heiden, M. Willeit, A. Konstantinidis, N. Thierry, S. Kasper (Department of General Psychiatry, University of Vienna, Vienna, Austria)

P41. The preliminary report of an outpatient, double-blind, placebo-controlled study comparing 30 mg and 45 mg of nemifitide versus placebo in major depression

S.A. Montgomery¹, J.P. Feighner², L. Sverdlov² (¹Imperial College, London, UK; ²Innapharma, Park Ridge, USA)
Audio-Visual Facilities

Equipment for computerised Power Point presentations is provided during the scientific sessions. Floppy disks and Cd-Rom for Power Point presentations can be tested prior to presentation in the slide preview room. Floppy disks or Cd-Rom must be handed over to the Slide preview Room at least forty minutes before the beginning of the sessions and must be collected directly by the speakers at the end of the session. **It is essential for the smooth running of the sessions that all speakers hand in their Power Point presentation in due time.**

European Accreditation

Following accreditation by EACCME, 15 credits have been granted in order to allow participants to validate the credits obtained at this activity in their own country. Those interested in obtaining these credits are required to fill in a special feedback rating form available in the congress bags or at the Secretariat Desk. Each medical specialist should claim only those hours of activity that he/she actually spends on the educational activity.

Certificate of Attendance

A certificate of attendance is provided on request at the registration desk on the last day of the congress.

Posters

All the accepted abstracts are scheduled for poster presentation. An area (Foyer) has been prepared for poster exhibition for viewing and discussing with the authors (especially during lunchtime and coffee breaks). Set up and removal times are as follows:

- Wednesday, November 19 from 09.00 to 11.00
- Friday, November 21 at 18.15

**Poster size : cm 150 height - cm 90 base**

Authors should be registered to the congress.
Badges

Participants are requested to wear their badge during all forum activities and social events. The participants’ registration fee includes admission to all scientific session and exhibition, forum material, welcome reception, coffee breaks and working lunches. Euro 30,00 is charged for replacement of a lost badge.

Congress badges are distinguished as follows:

- Participants: Transparent
- Speakers: Blue
- Exhibitors: Green
- Staff: Red

Congress Venue and Secretariat

The Congress Venue is the Monte Carlo Grand Hotel and all Congress material and documentation are available from the forum registration desk located in the foyer of the Hotel.

Opening hours

- Wednesday, November 19, 2003 11.00/20.00
- Thursday, November 20, 2003 08.00/20.00
- Friday, November 21, 2003 08.00/18.00

Coffee breaks and Lunches

During the Congress session breaks, coffee breaks and lunches are served free of charge to all registered participants, wearing Congress badges.
Electricity
The standard voltage in Monaco is 220 V.

Language
The official language of the Congress is English. No simultaneous translation is provided.

Insurance
The Congress organisers cannot accept liability for personal injuries sustained, or for loss or damage to property belonging to Congress participants, either during or as a result of the Congress. Registration does not include insurance.

Mobile phones
Delegates are kindly requested to keep their mobile phones in off position in the Room where the scientific sessions are held.

Smoking Policy
The 4th International Forum on Mood and Anxiety Disorders wishes to be a non-smoking congress. Participants are kindly requested to refrain from smoking in the congress venue, including exhibition area and restrooms.

Welcome Cocktail
All delegates are cordially invited to attend the Welcome Cocktail of the congress, which is held on Wednesday, November 19 at 19.00 in the foyer of the Monte Carlo Grand Hotel
Useful Telephone Numbers:

**Ambulance and Fire Services**  Ph +377 93301945 and 18

**Police**  Ph +377 93153015 and 17

**Monaco Hospital**  Ph +377 97989769
What to do in Monaco

Sites and attractions
The Principality has many interesting attractions: the Exotic Gardens, the Japanese Gardens situated right alongside the Mediterranean, and also the tourist train which will take you to explore the streets of Monaco. Visit the Old town where you can discover, in the narrow medieval alleyways, the Picturesque Place of Saint Nicolas and placette Bosio, the Cathedral, the Prince’s Palace and the Changing of the Guards which takes place every day at 11:55.

Museums
• The Oceanographic Museum dedicated to Marine science and rare species of fish
• The Wax museum depicting the history of Monaco’s princes and scenes from the Grimaldi dynasty
• The Exhibition of H.S.H. the Prince of Monaco’s Private collection of Classic cars: a collection of around 100 vehicles of all ages
• The Museum of Napoleonic Souvenirs: a collection of objects and documents relating to the 1st Empire
• The Naval Museum displaying over 180 models of famous boats
• The Museum of Prehistoric Anthropology with its collection of human and extinct animal remains from the archeological excavations of the region

But also outdoor sporting activities are enjoyed thanks to a very mild climate
• Tennis in the unique setting of the Monte-Carlo Country Club
• Golf on the 18 hole course of the Monte-Carlo Golf Club
And finally the pleasure of shopping in the excellent choice of stores present in the Principality: whether you are looking for clothes, or souvenirs, there are shopping centres and designers shops to satisfy all tastes.
ANNOUNCEMENT
OF NEXT FORUM

The 5th International Forum on Mood and Anxiety Disorders will be held in Monte-Carlo, November 18-20, 2004

Publi Créations - Partner of AIM

27, Bd. d'Italie - Monte Carlo - MC 98000 (Principality of Monaco)
Ph. +377 97973555 - Fax. +377 97973550
E-mail : ifmad@publiccreations.com
Cipralex®
– Fast, Effective and excellent Tolerability


Cipralex® Abbreviated Prescribing Information
Presentation: “Cipralex®”, tablets containing 10 mg escitalopram (as oxalate).
Indications: Major depression. Panic disorder with or without agoraphobia.
Dosage: Usual dose 10 mg once daily. Maximum dose 20 mg/day. In the elderly (>65 years), in panic disorder patients and in patients with reduced hepatic function an initial dose of 5 mg/day is recommended. Caution in patients with severely reduced renal function. Not recommended in children and adolescents (<18 years). When stopping treatment with escitalopram, the dose should be gradually reduced over a period of one or two weeks. Contraindications: Hypersensitivity to escitalopram. Concomitant treatment with non-selective MAOIs. Pregnancy and lactation: Careful consideration prior to use in pregnant women. Breast-feeding women should not be treated. Precautions: The special warnings and precautions which apply to the class of SSRIs. Drug interactions: Reversible, selective MAOIs. Segeline (irreversible MAO-B inhibitor). Medicinal products lowering the seizure threshold. St. John’s Wort. Enzyme inhibitors (e.g. omeprazole and cimetidine) may require reduction of escitalopram dose. Drugs metabolised by enzymes CYP 2D6 or 2C19. Adverse events: Adverse events, most frequent during first or second weeks, comprise the SSRI class adverse events, e.g. nausea, diarrhoea, and constipation. Overdosage: Dose of 190 mg escitalopram has been taken without any serious symptoms. Consult full prescribing information before prescribing.